Metric Analysis: Charles River Laboratories International Inc. (CRL)’s Key Ratios in the Limelight

For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.

In the latest session, Charles River Laboratories International Inc. (NYSE: CRL) closed at $232.56 down -0.11% from its previous closing price of $232.82. In other words, the price has decreased by -$0.11 from its previous closing price. On the day, 0.53 million shares were traded. CRL stock price reached its highest trading level at $238.22 during the session, while it also had its lowest trading level at $232.56.


For a deeper understanding of Charles River Laboratories International Inc.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 35.51 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 28.96. For the most recent quarter (mrq), Quick Ratio is recorded 1.37 and its Current Ratio is at 1.75. In the meantime, Its Debt-to-Equity ratio is 0.85 whereas as Long-Term Debt/Eq ratio is at 0.85.

On September 13, 2023, TD Cowen started tracking the stock assigning a Market Perform rating and target price of $212.

Citigroup Downgraded its Buy to Neutral on July 10, 2023, whereas the target price for the stock was revised from $260 to $225.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 10 ’24 when LaPlume Joseph W sold 1,304 shares for $226.97 per share. The transaction valued at 295,969 led to the insider holds 23,276 shares of the business.

Knell Michael Gunnar sold 808 shares of CRL for $216,156 on Mar 08 ’24. The CSVP&Chief Accounting Officer now owns 7,024 shares after completing the transaction at $267.52 per share. On Mar 04 ’24, another insider, Knell Michael Gunnar, who serves as the CSVP&Chief Accounting Officer of the company, sold 2,750 shares for $261.05 each. As a result, the insider received 717,890 and left with 7,832 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRL now has a Market Capitalization of 11979560960 and an Enterprise Value of 14797150208. As of this moment, Charles’s Price-to-Earnings (P/E) ratio for their current fiscal year is 27.01, and their Forward P/E ratio for the next fiscal year is 18.75. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.87. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.91 while its Price-to-Book (P/B) ratio in mrq is 3.29. Its current Enterprise Value per Revenue stands at 3.599 whereas that against EBITDA is 15.583.

Stock Price History:

The Beta on a monthly basis for CRL is 1.43, which has changed by 0.16711831 over the last 52 weeks, in comparison to a change of 0.2644323 over the same period for the S&P500. Over the past 52 weeks, CRL has reached a high of $275.00, while it has fallen to a 52-week low of $161.65. The 50-Day Moving Average of the stock is -6.45%, while the 200-Day Moving Average is calculated to be 6.71%.

Shares Statistics:

For the past three months, CRL has traded an average of 526.99K shares per day and 571300 over the past ten days. A total of 51.34M shares are outstanding, with a floating share count of 50.46M. Insiders hold about 2.04% of the company’s shares, while institutions hold 101.37% stake in the company. Shares short for CRL as of 1714435200 were 1899702 with a Short Ratio of 3.60, compared to 1711584000 on 1584730. Therefore, it implies a Short% of Shares Outstanding of 1899702 and a Short% of Float of 4.79.

Earnings Estimates

A comprehensive evaluation of Charles River Laboratories International Inc. (CRL) is underway, with the input of 12.0 analysts contributing to its current rating.On average, analysts expect EPS of $2.4 for the current quarter, with a high estimate of $2.53 and a low estimate of $2.36, while EPS last year was $2.69. The consensus estimate for the next quarter is $3.03, with high estimates of $3.18 and low estimates of $2.84.

Analysts are recommending an EPS of between $11.27 and $10.59 for the fiscal current year, implying an average EPS of $11.03. EPS for the following year is $12.4, with 15.0 analysts recommending between $12.93 and $11.88.

Revenue Estimates

A total of 12 analysts believe the company’s revenue will be $1.03B this quarter.It ranges from a high estimate of $1.06B to a low estimate of $1B. As of the current estimate, Charles River Laboratories International Inc.’s year-ago sales were $1.06BFor the next quarter, 12 analysts are estimating revenue of $1.07B. There is a high estimate of $1.09B for the next quarter, whereas the lowest estimate is $1.04B.

A total of 15 analysts have provided revenue estimates for CRL’s current fiscal year. The highest revenue estimate was $4.26B, while the lowest revenue estimate was $4.18B, resulting in an average revenue estimate of $4.22B. In the same quarter a year ago, actual revenue was $4.13BBased on 15 analysts’ estimates, the company’s revenue will be $4.54B in the next fiscal year. The high estimate is $4.71B and the low estimate is $4.43B.

Most Popular

[the_ad id="945"]